Subject(s)
Dermatomycoses/diagnosis , Trichosporon/isolation & purification , Trichosporonosis/diagnosis , Anti-Bacterial Agents/therapeutic use , Antifungal Agents/therapeutic use , Child, Preschool , Dermatomycoses/drug therapy , Dermatomycoses/microbiology , Humans , Male , Neutropenia/diagnosis , Trichosporonosis/drug therapy , Trichosporonosis/microbiologyABSTRACT
Contact immunotherapy is an increasingly used, effective means of treating cutaneous viral warts. Dinitrochlorobenzene, diphencyprone, and squaric acid dibutylester are the most frequently used modalities, showing slight variances in adverse effect profiles and efficacy. All of these agents serve as safe treatment modalities when administered according to the guidelines recommended herein. We review the value of contact immunotherapy in the treatment of cutaneous viral warts.
Subject(s)
Allergens/therapeutic use , Cyclobutanes/therapeutic use , Cyclopropanes/therapeutic use , Dinitrochlorobenzene/therapeutic use , Skin Diseases/drug therapy , Warts/drug therapy , Adjuvants, Immunologic/therapeutic use , Allergens/adverse effects , Cyclobutanes/adverse effects , Cyclopropanes/adverse effects , Dinitrochlorobenzene/adverse effects , HumansABSTRACT
The majority of toxic epidermal necrolysis (TEN) cases are provoked by "high risk" medications (e.g. allopurinol, aromatic anticonvulsants, nevirapine, oxicam non-steroidal anti-inflammatory agents, and sulfonamides). TEN usually occurs 1 to 8 weeks after initial administration of the offending agent, but re-administration can evoke TEN within hours to days. Hydroxychloroquine has rarely been associated with TEN, with one case proving fatal. Herein, we report a case of hydroxychloroquine-induced fatal TEN complicated by angioinvasive Rhizopus. To our knowledge, this is the first case report of angioinvasive Rhizopus in a TEN patient. Initial misidentification of the offending agent causing TEN also serves as an important teaching point worth highlighting.
Subject(s)
Antirheumatic Agents/adverse effects , Hydroxychloroquine/adverse effects , Mucormycosis/complications , Rhizopus , Stevens-Johnson Syndrome/etiology , Adult , Blood Vessels/microbiology , Facial Dermatoses/microbiology , Fatal Outcome , Female , Humans , Lupus Erythematosus, Systemic/drug therapy , Mucormycosis/microbiology , Necrosis/microbiology , Scalp Dermatoses/microbiology , Skin/pathologyABSTRACT
Plaque-like cutaneous mucinosis (PCM) is a rare disorder of dermal mucin deposition. Some patients with PCM will be found to have an associated malignancy. We report the case of a 72-year-old man presenting with new onset pruritic, waxy-appearing erythematous and skin-colored papules and nodules coalescing into plaques on his shoulder, scalp, and forehead. Skin biopsy revealed cutaneous mucinosis. Despite conservative treatment, his skin lesions progressed, and he was found to have an occult malignancy of pancreatobiliary origin. After several months of chemotherapy, his skin lesions showed progressive improvement. To our knowledge, this is the third reported case of paraneoplastic PCM and the first reported to occur in association with underlying adenocarcinoma of pancreatobiliary origin. PCM may occasionally represent a paraneoplastic dermatosis. This case highlights the importance of a search for occult malignancy in such patients.
Subject(s)
Adenocarcinoma/complications , Biliary Tract Neoplasms/complications , Mucinoses/complications , Pancreatic Neoplasms/complications , Skin Diseases/complications , Adenocarcinoma/diagnosis , Adenocarcinoma/drug therapy , Aged , Biliary Tract Neoplasms/diagnosis , Biliary Tract Neoplasms/drug therapy , Humans , Male , Mucinoses/pathology , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/drug therapy , Skin Diseases/pathologySubject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Ichthyosis/etiology , Lymphatic Diseases/etiology , Lymphoma, Large-Cell, Anaplastic/complications , Lymphoma, Large-Cell, Anaplastic/diagnosis , Skin/pathology , Aged , Cyclophosphamide/administration & dosage , Diagnosis, Differential , Doxorubicin/administration & dosage , Humans , Ichthyosis/pathology , Ichthyosis/therapy , Lymphoma, Large-Cell, Anaplastic/drug therapy , Male , Prednisolone/administration & dosage , Treatment Outcome , Vincristine/administration & dosage , Weight LossSubject(s)
Mosaicism , Sweat Gland Neoplasms/genetics , Sweat Gland Neoplasms/pathology , Humans , Male , Middle Aged , Neoplasm MetastasisSubject(s)
Collagen Diseases/pathology , Raynaud Disease/pathology , Skin Diseases, Vascular/pathology , Telangiectasis/pathology , Collagen Diseases/diagnosis , Collagen Type IV/metabolism , Female , Humans , Lower Extremity , Paresthesia/diagnosis , Paresthesia/pathology , Raynaud Disease/diagnosis , Skin Diseases, Vascular/diagnosis , Telangiectasis/diagnosis , Young AdultABSTRACT
Thyrotoxic induced hypokalemic periodic paralysis is a rare disorder that had been described in middle-aged men, predominantly Asians and Hispanics. This case presented with generalized weakness and hypokalemia after changing prescription for levothyroxine and starting prednisone to treat upper respiratory infection in a previously asymptomatic middle-aged Hispanic male. In this paper, we will go over the clinical presentation, mechanisms, and treatment of thyrotoxic induced hypokalemic periodic paralysis. Our objectives are to identify the classic constellation of findings in thyrotoxic periodic paralysis and to recognize the importance of considering thyrotoxic periodic paralysis among patients with hypokalemia.
